Plus completes enrollment in second ReSPECT-LM Phase 1 trial cohort

Plus Therapeutics announced completion of enrollment in Cohort 2 of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of rhenium obisbemeda for the treatment of leptomeningeal metastases, LM. "Based on the significant clinical need in LM and promising early data, we continue to see increasing interest from top U.S. cancer centers in the ReSPECT-LM Phase 1/2a trial," said Norman LaFrance, M.D., Chief Medical Officer and SVP of Plus Therapeutics. "Next steps, following the Data and Safety Monitoring Board review anticipated next month, will be completing enrollment in the Phase 1/Part A, followed by a meeting with the U.S. FDA to consider dose expansion in the Phase 1/Part B trial. Additionally, initial data from the Phase 1/Part A is anticipated in the second half of 2023." At the 2022 Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology, Plus Therapeutics presented Phase 1 data from the ReSPECT-LM trial demonstrating that a single administered dose of rhenium obisbemeda was feasible, safe and well-tolerated across two dosages in four patients from Cohorts 1 and 2, with patients experiencing a decreased cerebrospinal fluid tumor cell count at 48 hours following treatment of 46% to 92%.